CAMP4 Therapeutics (CAMP) vs InflaRx N.V. (IFRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CAMP4 Therapeutics (CAMP) has outperformed InflaRx N.V. (IFRX) over the past year, gaining 4.5% versus a gain of 4.1%. CAMP4 Therapeutics is the larger company by market cap ($236.6 million vs $235.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | IFRX |
|---|---|---|
| Share price | $3.77 | $1.60 |
| Market cap | $236.58M | $235.79M |
| 1-day change | +1.89% | +4.58% |
| YTD return | -39.64% | +51.49% |
| 1-year return | +4.52% | +4.08% |
| 5-year return | — | -38.06% |
| EPS (TTM) | $-2.32 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $2.95 |
| 52-week low | $2.86 | $0.798 |
| Distance from 52-week high | -51.35% | -45.74% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +180.37% | +380.00% |
| Average volume | 279.32K | 798.72K |
| Shares outstanding | 62.75M | 147.37M |
| Employees | 48 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
CAMP vs IFRX FAQ
Which is bigger, CAMP4 Therapeutics or InflaRx N.V.?
CAMP4 Therapeutics (CAMP) is larger, with a market capitalization of $236.58M compared with $235.79M for InflaRx N.V. (IFRX).
Which stock has performed better over the past year, CAMP or IFRX?
CAMP returned +4.52% over the past 12 months, compared with +4.08% for IFRX (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and InflaRx N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.